CA3243621A1 - METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS - Google Patents

METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS

Info

Publication number
CA3243621A1
CA3243621A1 CA3243621A CA3243621A CA3243621A1 CA 3243621 A1 CA3243621 A1 CA 3243621A1 CA 3243621 A CA3243621 A CA 3243621A CA 3243621 A CA3243621 A CA 3243621A CA 3243621 A1 CA3243621 A1 CA 3243621A1
Authority
CA
Canada
Prior art keywords
compound
formula
salt
pct
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243621A
Other languages
English (en)
French (fr)
Inventor
Alonso Jose ARGUELLES DELGADO
Boris Arnoldovich CZESKIS
Mai Khanh Nguyen HAWK
Douglas Patton Kjell
Yu Lu
Nicholas Andrew Magnus
David Michael Remick
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3243621A1 publication Critical patent/CA3243621A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CA3243621A 2022-02-01 2023-01-27 METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS Pending CA3243621A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22
PCT/US2023/011671 WO2023150056A1 (en) 2022-02-01 2023-01-27 Processes for the preparation of selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
CA3243621A1 true CA3243621A1 (en) 2023-08-10

Family

ID=85382684

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243621A Pending CA3243621A1 (en) 2022-02-01 2023-01-27 METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TWI863110B (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
MD3820874T2 (ro) 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
CN115175679A (zh) 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
JP7387926B2 (ja) 2023-11-28
MX2024009453A (es) 2024-08-09
EP4472982A1 (en) 2024-12-11
US11926634B2 (en) 2024-03-12
JP2023112696A (ja) 2023-08-14
KR102743629B1 (ko) 2024-12-17
AU2025234145A1 (en) 2025-10-02
KR20250006312A (ko) 2025-01-10
US20230242545A1 (en) 2023-08-03
DOP2024000150A (es) 2024-08-30
AU2023216654B2 (en) 2025-09-25
TWI863110B (zh) 2024-11-21
JOP20240169A1 (ar) 2024-07-30
TW202523669A (zh) 2025-06-16
KR20240135862A (ko) 2024-09-12
CO2024009411A2 (es) 2024-07-29
JP2023162334A (ja) 2023-11-08
IL313886A (en) 2024-08-01
CR20240283A (es) 2024-09-03
WO2023150056A1 (en) 2023-08-10
JP7805336B2 (ja) 2026-01-23
TW202346300A (zh) 2023-12-01
PE20241731A1 (es) 2024-08-19
AU2023216654A1 (en) 2024-07-11
JP2025183283A (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
US8431694B1 (en) Process for making thienopyrimidine compounds
JP6966423B2 (ja) 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用
AU2025234145A1 (en) Processes for the preparation of selective estrogen receptor degraders
AU2020259384A1 (en) Dihydroorotate dehydrogenase inhibitors
JP2022513934A (ja) 置換複素環縮合γ－カルボリンの合成
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
CN108137588B (zh) 三环稠合吡啶-2-酮衍生物及其作为brd4抑制剂的用途
CN107548393B (zh) 适用于治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物
JP6332818B2 (ja) チカグレロルの中間体およびその製造法、およびチカグレロルの製造法
CA3223714A1 (en) Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
CN102216274A (zh) (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
BR112024013443B1 (pt) Processos para a preparação de degradadores seletivos de receptores de estrogênio
CN118647619A (zh) 选择性雌激素受体降解剂的制备方法
BR122025017409A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
BR122025017416A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
CN120757498A (zh) 一种3-氨基取代2-喹啉酮类化合物及其制备方法和应用
HK1248686B (zh) 适用於治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240801

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240802

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240802

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240802

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241002

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223